Pharmacogenetics of esomeprazole or rabeprazole‐based triple therapy in Helicobacter pylori eradication in Hong Kong non‐ulcer dyspepsia Chinese subjects

Objective:  Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non‐ulcer dyspepsia (NUD) patients.

[1]  B. C. Wong,et al.  Treatment of Helicobacter pylori and prevention of gastric cancer , 2008, Journal of digestive diseases.

[2]  F. Chan,et al.  Levofloxacin-Resistant Helicobacter pylori in Hong Kong , 2007, Chemotherapy.

[3]  R. Hunt,et al.  The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis , 2006, The American Journal of Gastroenterology.

[4]  A. Kao,et al.  Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism , 2005 .

[5]  H. Allgayer.  Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[6]  J. Hatlebakk.  Review article: gastric acidity − comparison of esomeprazole with other proton pump inhibitors , 2003, Alimentary pharmacology & therapeutics.

[7]  M. Kasuga,et al.  Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan , 2003, European journal of gastroenterology & hepatology.

[8]  J. Sung,et al.  The Antimicrobial Susceptibility of Helicobacter pylori in Hong Kong (1997–2001) , 2002, Helicobacter.

[9]  O. Junghard,et al.  The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH , 2002, European Journal of Clinical Pharmacology.

[10]  L. Laine.  Esomeprazole in the treatment of Helicobacter pylori , 2002 .

[11]  K. Yokota,et al.  Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype , 2002, Journal of gastroenterology and hepatology.

[12]  J. Goldstein,et al.  Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. , 2002, Pharmacogenetics.

[13]  M. Onda,et al.  Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations , 2001, Journal of Gastroenterology.

[14]  M. Asaka,et al.  Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism , 2001, Alimentary pharmacology & therapeutics.

[15]  S. B. des Varannes,et al.  There are some benefits for eradicating Helicobacter pylori in patients with non‐ulcer dyspepsia , 2001, Alimentary pharmacology & therapeutics.

[16]  T. Azuma,et al.  Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  M. Simadibrata,et al.  HELICOBACTER PYLORI IN GASTRIC CANCER , 2000 .

[18]  Y. Tanigawara,et al.  CYP2C19 genotype–related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori , 1999 .

[19]  E. Boyle,et al.  Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis , 1999, BMJ.

[20]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[21]  D. Forman.  Helicobacter pylori: the gastric cancer problem , 1998, Gut.

[22]  H. Müller-Hermelink,et al.  MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. , 1997, Gastroenterology.

[23]  J. Goldstein,et al.  Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[25]  C. O'Morain,et al.  Helicobacter pylori Infection , 1994 .

[26]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[27]  M. Cavazza,et al.  Antimicrobial susceptibility of helicobacter pylori , 2003 .

[28]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.